Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis

Phase 2 Completed 182 enrolled Janssen Research & Development, LLC

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.

Timeline

Start: 2023-11-06
Primary completion: 2025-07-14
Completion: 2025-08-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PIPE-307	Unknown	—	Oral

Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis

Summary

Timeline

Drugs

Indications